Trial reportAmerican journal of hypertension2016
Effect of Intensive Blood Pressure Lowering on Incident Atrial Fibrillation and P-Wave Indices in the ACCORD Blood Pressure Trial.
Trial report in American journal of hypertension, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000620. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026Guideline
- Effect of intensive blood pressure lowering on left atrial remodeling in the SPRINT.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Trial
- Effect of Intensive Blood Pressure Lowering on the Risk of Atrial Fibrillation.Hypertension (Dallas, Tex. : 1979) · 2020Trial
- Incidence and Implications of Atrial Fibrillation/Flutter in Hypertension: Insights From the SPRINT Trial.Hypertension (Dallas, Tex. : 1979) · 2020Trial
- Hypertension and Atrial Fibrillation: Bridging the Gap Between Mechanisms, Risk, and Therapy.Medicina (Kaunas, Lithuania) · 2025Review
- The Role of Early Risk Factor Modification and Ablation in Atrial Fibrillation Substrate Remodeling Prevention.Biomedicines · 2025Review
- New-onset hypertension as a contributing factor to the incidence of atrial fibrillation in the elderly.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Epidemiology and modifiable risk factors for atrial fibrillation.Nature reviews. Cardiology · 2023Review
- Blood pressure status affects atrial fibrillation in diabetic end-stage renal disease.PloS one · 2023Article
- Relationship Between High Blood Pressure, Atrial Cardiopathy, and Mortality in the General Population.American journal of hypertension · 2023Article
- The Impact of Hypertension and Atrial Fibrillation on Cognitive Decline and Subclinical Atherosclerosis.Brain sciences · 2021Article
- Integrated Care in Atrial Fibrillation: A Road Map to the Future.Circulation. Cardiovascular quality and outcomes · 2021Review
- Genetically Predicted Blood Pressure and Risk of Atrial Fibrillation.Hypertension (Dallas, Tex. : 1979) · 2021Article
- What Is the Ideal Blood Pressure Threshold for the Prevention of Atrial Fibrillation in Elderly General Population?Journal of clinical medicine · 2020Article
- A Nurse-led Approach to Improving Cardiac Lifestyle Modification in an Atrial Fibrillation Population.The Journal of innovations in cardiac rhythm management · 2019Article
- Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation.Journal of diabetes research · 2019Review
- Blood pressure targets for hypertension in patients with type 2 diabetes.Annals of translational medicine · 2018Article
- Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart Association.Circulation · 2018Review
- Electrocardiogram (ECG) for the Prediction of Incident Atrial Fibrillation: An Overview.Journal of atrial fibrillation · 2017Review
- Carotid Intima-Media Thickness and Arterial Stiffness and the Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study, Multi-Ethnic Study of Atherosclerosis (MESA), and the Rotterdam Study.Journal of the American Heart Association · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThere are no proven strategies to prevent atrial fibrillation (AF) in patients with type 2 diabetes (T2DM). We compared standard blood pressure (BP) lowering vs. intensive BP lowering in reducing incidence of AF or P-wave indices (PWI-ECG markers of left atrial abnormality that are considered intermediate phenotypes of AF) in patients with T2DM.
methodsWe analyzed data from the ACCORD BP trial-a randomized controlled nonblinded trial (2001-2009) which randomized patients with T2DM and systolic BP (SBP) 130-180mm Hg on ≤3 antihypertensive medications aged 40-79 years with cardiovascular disease (CVD) or aged 55-79 years with subclinical CVD or ≥2 CVD risk factors to standard BP lowering (SBP <140mm Hg) vs. intensive BP lowering (SBP <120mm Hg). The primary outcome was a composite of incident AF and PWI.
resultsData from 3,087 participants (mean age, 62.2 years; women, 48.2%; non-White, 39.2%) were analyzed. During a mean follow-up of 4.4 years, the primary outcome occurred in 1,063 participants (incidence rate, 84.5 per 1,000 person-years in the standard-therapy group vs. 73.9 per 1,000 person-years in the intensive-therapy group). The adjusted hazard ratios (95% confidence intervals) of intensive-therapy group for the primary outcome and for incident PWI alone were 0.87 (0.77-0.98), P = 0.02 and 0.87 (0.76-0.98), P = 0.02, respectively. The effect of intensive therapy on the incidence of AF alone did not reach statistical significance.
conclusionsIn patients with T2DM, intensive BP lowering reduces the incidence of the composite outcome of AF and PWI, suggesting a potential benefit from stringent BP control in patients with T2DM. clinical trials registration Trial Number NCT00000620.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.